Biologics

The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.

Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.

Aviv Regev is betting AI-driven drug discovery can transform Genentech's pipeline, with early wins validating her computational biology approach to pharmaceutical R&D.

In this episode of the In Vivo podcast, Lupus Therapeutics' Stacie Bell discusses transforming lupus drug development through patient-centered clinical trials, promising new oral therapies and revolutionary cell therapy approaches.

Halozyme’s move to acquire the developer of subcutaneous drug-delivery technology for biologics expands its options for partnering and developing products available for at-home and health care provider office delivery.

Multiple Korean ministries, biopharma companies, and other officials convened at a bio innovation roundtable to discuss strategies to emerge as a global biopharma powerhouse.

“We’ve invested billions of dollars and have achieved over $12bn in revenues since we launched our first biosimilars,” Amgen’s biosimilars head, Marc Doble, tells Generics Bulletin as part of an exclusive interview, which explores how the firm’s biosimilars benefit from its roots in biologics.

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.

Celltrion is the preferred bidder for the acquisition of a large-scale cGMP biologics manufacturing plant in the US, marking a pivotal move to localize production and secure its US pharmaceutical business against rising tariff risks.

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.